3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
61
Recurrence
10
Lymphoma
5
Waldenstrom Macroglobulinemia
4
Neoplasms, Plasma Cell
4
Small Cell Lung Carcinoma
3
Ovarian Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Kidney Neoplasms
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Sezary Syndrome
1
Salivary Gland Adenoma, Pleomorphic
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Plasmacytoma
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Plasma Cell
1
Leukemia
1
Kidney Failure, Chronic
1
Interventions
Lenalidomide
2
Dexamethasone
2
Bortezomib
2
posaconazole
1
carfilzomib
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Bone Marrow Neoplasms
×
carfilzomib
×
Clear all
NCT03859427
2024-08-13
ARROW2
Amgen
Phase 3
Completed
454 enrolled
24 charts